Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Moleculin Biotech (MBRX) Assets Average (2016 - 2025)

Moleculin Biotech's Assets Average history spans 10 years, with the latest figure at $21.2 million for Q4 2025.

  • Quarterly results put Assets Average at $21.2 million for Q4 2025, up 5.36% from a year ago — trailing twelve months through Dec 2025 was $21.2 million (up 5.36% YoY), and the annual figure for FY2025 was $19.5 million, down 29.18%.
  • Assets Average for Q4 2025 was $21.2 million at Moleculin Biotech, up from $21.0 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $96.7 million in Q2 2021 to a low of $19.0 million in Q1 2025.
  • The 5-year median for Assets Average is $46.2 million (2023), against an average of $50.1 million.
  • The sharpest move saw Assets Average skyrocketed 240.04% in 2021, then plummeted 48.14% in 2024.
  • Year by year, Assets Average stood at $86.4 million in 2021, then dropped by 28.94% to $61.4 million in 2022, then crashed by 36.69% to $38.9 million in 2023, then crashed by 48.14% to $20.2 million in 2024, then increased by 5.36% to $21.2 million in 2025.
  • According to Business Quant data, Assets Average over the past three periods came in at $21.2 million, $21.0 million, and $21.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.